Publication Name	World Journal of Gastroenterology
Manuscript ID	45668
Country	United States

Category	Gastroenterology & Hepatology
Manuscript Type	Clinical Trials Study
Article Title	Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
Manuscript Source	Unsolicited Manuscript
All Author List	Nicole Loo, Eric Lawitz, Naim Alkhouri, Jennifer Wells, Carmen Landaverde, Angie Coste, Rossalynn Salcido, Michael Scott and Fred Poordad
Funding Agency and Grant Number	Funding Agency Grant Number AbbVie B15-791
Corresponding Author	Fred Poordad, MD, Attending Doctor, Professor, Academic and Clinical Affairs, Texas Liver Institute, 607 Camden Street, San Antonio, TX 78215, United States. poordad@txliver.com
Key Words	HHepatitis C; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Genotype 1
Core Tip	The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), HCV NS4/4A protease inhibitor ABT-450 (paritaprevir, PTV), CYP3A inhibitor ritonavir (r) and non-nucleoside NS5B polymerase inhibitor ABT-333 (dasabuvir, DSV) (OBV/PTV/r + DSV) with or without ribavirin (RBV) is an approved direct-acting antiviral regimen less frequently studied in an all-comers population. This study included 96 all-comers; many had comorbidities (44.2% hypertensive, 33.7% obese, 20.2% cirrhotic) and 16% previously failed HCV treatment. In these patients, 12 or 24-wk of OBV/PTV/r + DSV +/- RBV was highly effective (99% sustained virologic response for 12 wk treatment), tolerable and resulted in better mental and physical health.
Citation	Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M and Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239

Received	2019-02-03 14:52
Peer-Review Started	2019-02-06 06:18
To Make the First Decision	2019-03-14 06:21
Return for Revision	2019-03-15 02:49
Revised	2019-03-21 18:30
Second Decision	2019-04-04 08:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-04-10 21:42
Articles in Press	2019-04-10 21:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-05-14 00:31

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com